ABVC BioPharma (NASDAQ:ABVC) Trading Down 4.9% – Here’s What Happened

ABVC BioPharma, Inc. (NASDAQ:ABVC)’s stock price was down 4.9% during mid-day trading on Monday . The stock traded as low as $2.30 and last traded at $2.31. Approximately 73,821 shares were traded during mid-day trading, a decline of 2% from the average daily volume of 75,496 shares. The stock had previously closed at $2.43.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ABVC BioPharma in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

ABVC BioPharma Trading Down 4.9%

The firm has a market cap of $56.13 million, a P/E ratio of -11.55 and a beta of 0.24. The company’s 50-day moving average is $2.59 and its two-hundred day moving average is $2.81.

ABVC BioPharma (NASDAQ:ABVC) last issued its quarterly earnings data on Friday, October 31st. The company reported ($0.05) EPS for the quarter. The business had revenue of $0.80 million during the quarter.

Institutional Investors Weigh In On ABVC BioPharma

A number of institutional investors and hedge funds have recently bought and sold shares of ABVC. Citadel Advisors LLC bought a new position in ABVC BioPharma during the 3rd quarter valued at $48,000. Millennium Management LLC purchased a new stake in shares of ABVC BioPharma in the third quarter valued at about $60,000. Finally, Geode Capital Management LLC lifted its position in shares of ABVC BioPharma by 5.8% during the second quarter. Geode Capital Management LLC now owns 110,499 shares of the company’s stock valued at $246,000 after purchasing an additional 6,017 shares in the last quarter. 11.38% of the stock is owned by hedge funds and other institutional investors.

ABVC BioPharma Company Profile

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.